Aug. 1, 2019: Raltegravir OK in pregnancy; HIV disclosure and viral suppression among pregnant women; newborn size following HIV exposure; causes of hearing problems among people with HIV.
World Health Organization Updates Guidance on Dolutegravir After Reassuring Data Regarding Safety in Early Pregnancy
New study results leave many experts feeling they went too far in their concerns over birth defect risks associated with the drug.
Six thousand HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
June 6, 2019: HIV/STI risk perceptions differ by race; psychosocial issues and HIV risk among young trans women; switching to dolutegravir/atazanavir; reports of severe hepatotoxicity on dolutegravir.
This will likely become the landmark study about the overall rate of neuropsychiatric side effects with this class of medicines over the next several years.
Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows
Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.
A Canadian study of this cost-saving approach found high acceptance of de-simplification among people already on a single-tablet regimen, and even higher rates among people who were just initiating single-tablet treatment.
Integrase inhibitors are associated with greater increases in body weight than other antiretrovirals, especially among women and black people. But it's unclear whether these changes are clinically significant.
In clinical trials called Sword 1 and Sword 2, researchers testing a combination of dolutegravir/rilpivirine (Juluca) found it to be effective and tolerable.
In 2018, the same year we learned that a two-drug initial HIV treatment regimen featuring dolutegravir (Tivicay, DTG) was viable for many of our patients, we also got a much-less-welcome dolutegravir (Tivicay, DTG)-related surprise. Early in the year...